| Primary |
| Drug Use For Unknown Indication |
24.2% |
| Type 2 Diabetes Mellitus |
18.0% |
| Diabetes Mellitus |
17.7% |
| Product Used For Unknown Indication |
12.9% |
| Hypertension |
7.9% |
| Diabetes Mellitus Non-insulin-dependent |
3.7% |
| Insulin-requiring Type Ii Diabetes Mellitus |
3.4% |
| Gout |
1.3% |
| Respiratory Tract Infection |
1.3% |
| Dyslipidaemia |
1.1% |
| Herpes Virus Infection |
1.1% |
| Pain |
1.0% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Depression |
0.9% |
| Hiv Infection |
0.9% |
| Myocardial Infarction |
0.9% |
| Anxiety |
0.7% |
| Arrhythmia |
0.7% |
| Atrial Fibrillation |
0.7% |
| Cardiac Failure |
0.7% |
|
| Hypoglycaemia |
19.1% |
| Hypoglycaemic Coma |
14.2% |
| Hypoglycaemic Unconsciousness |
6.4% |
| Renal Failure |
6.4% |
| Somnolence |
5.0% |
| Thrombocytopenia |
5.0% |
| Death |
4.3% |
| Renal Failure Acute |
4.3% |
| Cytolytic Hepatitis |
3.5% |
| Respiratory Failure |
3.5% |
| Vomiting |
3.5% |
| Acute Respiratory Failure |
2.8% |
| Drug Eruption |
2.8% |
| Hepatitis Toxic |
2.8% |
| Macular Oedema |
2.8% |
| Pulmonary Oedema |
2.8% |
| Sopor |
2.8% |
| Urinary Tract Infection |
2.8% |
| Vasculitis |
2.8% |
| Anaemia Haemolytic Autoimmune |
2.1% |
|
| Secondary |
| Drug Use For Unknown Indication |
22.9% |
| Type 2 Diabetes Mellitus |
18.0% |
| Diabetes Mellitus |
11.9% |
| Hypertension |
10.1% |
| Product Used For Unknown Indication |
8.6% |
| Unevaluable Event |
6.4% |
| Premedication |
3.3% |
| Diabetes Mellitus Non-insulin-dependent |
2.4% |
| Essential Hypertension |
2.0% |
| Pain |
1.8% |
| Atrial Fibrillation |
1.4% |
| Coronary Artery Disease |
1.4% |
| Lung Infection |
1.4% |
| Cardiac Failure |
1.3% |
| Prostate Cancer |
1.3% |
| Infection |
1.2% |
| Bronchopneumopathy |
1.1% |
| Dyslipidaemia |
1.1% |
| Ill-defined Disorder |
1.1% |
| Insulin-requiring Type Ii Diabetes Mellitus |
1.1% |
|
| Hypoglycaemia |
17.0% |
| Vomiting |
8.1% |
| Renal Failure Acute |
7.4% |
| Transaminases Increased |
6.7% |
| Death |
5.9% |
| Pancreatitis Acute |
5.9% |
| Syncope |
5.9% |
| Thrombocytopenia |
5.9% |
| Renal Failure |
5.2% |
| Eczema |
4.4% |
| Injection Site Urticaria |
4.4% |
| Somnolence |
3.0% |
| Suicide Attempt |
3.0% |
| Thrombocytopenic Purpura |
3.0% |
| Weight Increased |
3.0% |
| Anaemia Haemolytic Autoimmune |
2.2% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.2% |
| Face Oedema |
2.2% |
| Pneumonia |
2.2% |
| Purpura |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
24.6% |
| Product Used For Unknown Indication |
18.9% |
| Hypertension |
13.2% |
| Diabetes Mellitus |
12.6% |
| Type 2 Diabetes Mellitus |
9.4% |
| Rheumatoid Arthritis |
4.1% |
| Prophylaxis |
2.0% |
| Atrial Fibrillation |
1.8% |
| Depression |
1.7% |
| Hiv Infection |
1.3% |
| Pain |
1.3% |
| Pneumonia |
1.2% |
| Hypercholesterolaemia |
1.1% |
| Hypothyroidism |
1.1% |
| Lung Disorder |
1.0% |
| Myocardial Infarction |
1.0% |
| Mycobacterium Avium Complex Infection |
0.9% |
| Chronic Myeloid Leukaemia |
0.9% |
| Osteoporosis |
0.9% |
| Breast Cancer |
0.9% |
|
| Renal Failure Acute |
16.0% |
| Vomiting |
10.4% |
| Weight Decreased |
8.3% |
| Thrombocytopenia |
7.4% |
| Renal Failure |
7.1% |
| Weight Increased |
5.2% |
| International Normalised Ratio Increased |
4.6% |
| Somnolence |
4.6% |
| Urinary Retention |
4.0% |
| Urinary Tract Infection |
4.0% |
| Pancreatitis |
3.4% |
| Transaminases Increased |
3.4% |
| Vision Blurred |
3.4% |
| Myocardial Infarction |
2.8% |
| Pneumonia |
2.8% |
| Pulmonary Embolism |
2.8% |
| Pyrexia |
2.8% |
| General Physical Health Deterioration |
2.5% |
| Hyponatraemia |
2.5% |
| Pain |
2.5% |
|
| Interacting |
| Type 2 Diabetes Mellitus |
25.7% |
| Hypertension |
13.3% |
| Pain |
8.0% |
| Drug Use For Unknown Indication |
7.1% |
| Cardiac Failure |
5.3% |
| Coronary Artery Disease |
5.3% |
| Dyslipidaemia |
5.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
5.3% |
| Osteoporosis |
3.5% |
| Restless Legs Syndrome |
3.5% |
| Hyperparathyroidism Secondary |
2.7% |
| Nausea |
2.7% |
| Renal Failure |
2.7% |
| Vitamin Supplementation |
2.7% |
| Chronic Obstructive Pulmonary Disease |
1.8% |
| Prophylaxis |
1.8% |
| Diabetes Mellitus |
0.9% |
| Hyperkalaemia |
0.9% |
| Hyperparathyroidism |
0.9% |
| Hyperphosphataemia |
0.9% |
|
| Hypoglycaemia |
47.1% |
| Transaminases Increased |
29.4% |
| Potentiating Drug Interaction |
11.8% |
| Drug Interaction |
5.9% |
| Psoriasis |
5.9% |
|
